Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.
Clinical trial update describing a study on how venetoclax plasma levels relate to toxicity when combined with hypomethylating agents in pat…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
This is a compassionate-use clinical trial in France enrolling adults with acute myeloid leukemia to receive ivosidenib (Tibsovo). The study…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
A completed clinical trial evaluating oral venetoclax in adults with acute myeloid leukemia to assess adverse events and changes in disease …
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia [Phase 3]
Update on a Phase 3 pivotal trial evaluating APG-2575 (Lisaftoclax) in combination with Azacitidine for acute myeloid leukemia; the study is…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Study of the Medullary Microenvironment in Acute Childhood Leukemia [NA]
A pediatric clinical trial is investigating the medullary microenvironment in acute lymphoblastic leukemia and acute myeloid leukemia; the s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
A Phase 1 clinical trial of CT0991 for relapsed/refractory acute myeloid leukemia has been suspended.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Maintenance Venetoclax in AML Fit Patients [NA]
This clinical trial update notes that maintenance venetoclax is being studied in fit patients with acute myeloid leukemia and is currently r…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]
This document provides a Phase 2 update on a recruiting trial evaluating CPX-351 plus Ivosidenib for IDH1-mutated acute myeloid leukemia and…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT [NA]
Clinical trial evaluating the combination of a PD-1 inhibitor, azacitidine, and low-dose donor lymphocyte infusion for relapse of acute myel…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia [Phase 2]
A Phase 2 clinical trial is evaluating the triple combination of venetoclax, azacitidine, and chidamide (VAC) for newly diagnosed acute mono…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Pilot Study of Reduced Venetoclax Exposure [Phase 2]
Phase 2 pilot study updating on reduced venetoclax exposure in patients with acute myeloid leukemia in remission; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Veliparib and Temozolomide in Treating Patients With Acute Leukemia [Phase 1]
Phase 1 study of veliparib plus temozolomide in adults with acute lymphoblastic leukemia or acute myeloid leukemia has completed enrollment,…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia [Phase 3]
A Phase 3 clinical trial in Russia evaluating the efficacy of a therapy for patients with acute myeloid leukemia and Down syndrome is curren…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: VYxeoS Liposomal Italian Observational Study iN the Real Practice
A real-world observational study in Italy evaluating Vyxeos (CPX-351) for acute myeloid leukemia and its subtypes has completed.
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 clinical trial evaluating decitabine, venetoclax, and ponatinib for Philadelphia chromosome-positive acute myeloid leukemia and rela…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor [Phase 2]
Phase 2 clinical trial update evaluating post-transplantation benadamustine and cyclophosphamide in high-risk myeloid malignancies with part…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia [NA]
This clinical trial is evaluating the safety and efficacy of gamma-delta T cell therapy to prevent relapse after allogeneic transplantation …
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 study evaluating venetoclax-based regimens with azacitidine, including combinations with cladribine or chidamide, or alternating VAC…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia [Phase 1, Phase 2]
This document describes a Phase 1/2 clinical trial evaluating the combination of gilteritinib and momelotinib in relapsed or refractory FLT3…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
A Phase 1 trial of regorafenib in combination with venetoclax and azacitidine for relapsed or refractory acute myeloid leukemia has been sus…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells [NA]
A clinical study is planned to evaluate selinexor-based chemotherapy with minimal or no cytotoxic agents in treatment-naïve acute myeloid le…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia [Phase 2]
A Phase 2 trial is evaluating the safety and efficacy of FT14 conditioning for allogeneic hematopoietic stem cell transplantation in patient…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: The Mutation Profile and Prognosis in AML With IDH1/2 Mutation
Clinical trial update on mutation profile and prognosis for acute myeloid leukemia patients with IDH1/2 mutations; the study status is termi…
-
CLINICAL_TRIALS other · 2025-11-18Clinical Trial Update: A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 trial update for CT0991 in relapsed/refractory acute myeloid leukemia shows the study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy [Phase 2]
A Phase 2 study evaluating MBG453 in combination with azacitidine and venetoclax in AML patients unfit for chemotherapy has been terminated …